MedTrace Logo

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

NCT00454883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 379

Last updated 2021-02-21

No results posted yet for this study

Summary

Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.

Conditions

  • Affective Psychosis, Bipolar
  • Mania
  • Manic-Depressive Psychosis

Interventions

DRUG

ziprasidone

Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00454883 on ClinicalTrials.gov